Rep. DeLaRosa supports HB4327 mandating auditor general review of 340B Drug Discount Program

Rep. Margaret A. DeLaRosa (D-42nd) cast her vote in favor of HB4327 on May 31, 2026, during the 104th General Assembly. The legislation, intended to require the auditor general to audit the 340B Drug Discount Program, passed the Illinois House with a 106-8 majority, records from the Illinois House show.

According to the official bill description: "AUDITOR GENERAL-340B AUDIT."

Below is a synopsis reflecting the bill's provisions, clarified with nonpartisan interpretation.

The bill instructs the Illinois auditor general to launch, as soon as practical following enactment, a thorough review of the involvement of 340B covered entities in the federal 340B Drug Discount Program within the state. The audit is set to investigate profit margins on 340B medications, expenses involving third-party administrators, payments made to pharmacy benefit managers and contract pharmacies, the structure of drug ownership contracts at pharmacy sites, the standard markups on 340B-priced pharmaceuticals, and how frequently patient discounts are extended at the point of sale to vulnerable residents. Its findings and recommended changes will be reported to the General Assembly.

The action officially logged for HB4327 was 'Senate Committee Amendment No. 1 House Concurs.'

DeLaRosa is a DePaul University graduate, holding a BS degree.

A Democrat, DeLaRosa was elected in 2025 to serve in the Illinois State House for the 42nd District, succeeding Terra Costa Howard.

The legislative process in Illinois involves a multi-step review: bills start in either the House or Senate, undergo committee consideration, floor debate, and must win passage in both legislative bodies before being submitted to the governor for signature or veto. The General Assembly meets on a biennial basis. Out of the thousands of proposals introduced during each session, only a select few ultimately become law.